Amgen Inc.'s fourth-quarter net income fell 32%, to $91.1 million, or 64 cents a share, from the year-earlier quarter in which it recorded a hefty legal award.
The results were in line with analysts' estimates, and eased investor fears about weak sales of its Neupogen cancer-treatment drug.
In the prior year, the Thousand Oaks, Calif.-based biotechnology concern had net income of $133.8 million, or 91 cents a share.
That amount included $50.9 million, or 35 cents a share, from the legal award.
Revenue rose 18.6% to $365.6 million from $308.2 million, Amgen said in a report issued after the market closed yesterday.
Amgen closed at $47, down $1.75, in Nasdaq Stock Market trading yesterday.
For all of 1993, Amgen net income rose 7.2% to $383.3 million, or $2.67 a share, from $357.6 million, or $2.43 a share.
Revenue rose 25.7% to $1.37 billion from $1.09 billion.
